GlassScriptPhysician profile
Fadi Nakhl
NPI 1720242704
$16,401.61
in general payments reported to CMS, 2019-2025
75 companies · $2,681 in 2025
The $2,681 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,546 · 2020: $743 · 2021: $3,636 · 2022: $4,653 · 2023: $1,988 · 2024: $1,155 · 2025: $2,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,419 · Education: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,419.17 |
| Education | $404.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,096.46 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $988.24 | 2019-2025 | |
| Janssen Biotech, INC. | $910.20 | 2019-2025 | Erleada, Talvey, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $835.30 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Merck Sharp & Dohme LLC | $757.52 | 2019-2025 | Keytruda, Lynparza |
| Lilly USA, LLC | $650.64 | 2019-2025 | Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $636.64 | 2019-2025 | Enhertu, Calquence, Tagrisso |
| Genentech USA, INC. | $633.28 | 2019-2025 | Itovebi, Tecentriq, Venclexta |
| Incyte Corporation | $617.64 | 2019-2025 | Monjuvi, Zynyz, Jakafi |
| Astellas Pharma US INC | $597.36 | 2019-2024 | |
| Eisai INC. | $597.08 | 2019-2025 | |
| Celgene Corporation | $551.48 | 2020-2025 | Reblozyl, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $529.47 | 2019-2025 | |
| Genzyme Corporation | $399.79 | 2019-2025 | |
| Amgen INC. | $375.36 | 2019-2022 |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Nakhl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.